Shuttle Pharmaceuticals Holdings, Inc. plans to list on the Nasdaq Capital Market under the symbol SHPH. It filed a Form S-1 registration statement for an initial public offering on September 20, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, October 31, 2024).
Who owns Shuttle Pharmaceuticals Holdings, Inc.?
Sell to companies like Shuttle Pharmaceuticals Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Shuttle Pharmaceuticals Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-20. It has amended it 4 times. It filed its final prospectus on 2024-10-31. Each fact below is quoted from the filing named with it.
Layoffs on record: 1 filing or notice, latest 2025-11-21 (layoff filings and notices).
Also on the record for Shuttle Pharmaceuticals Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Form D, private offering | $9.96M sold | Form D page | Source |
| May 7, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| November 7, 2025 | Form D, private offering | $2.50M sold | Form D page | Source |
| June 26, 2025 | Form D, private offering | $4.25M sold | Form D page | Source |
Check before you invest in Shuttle Pharmaceuticals Holdings, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Shuttle Pharmaceuticals Holdings, Inc. and the records around it.
Shuttle Pharmaceuticals Holdings, Inc. elsewhere on the record
- Company profile and every filing May 2026
- Form D filing May 2026
- Layoff notices Nov 2025
- Form D filing Nov 2025
- Who owns it
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q1 2026, newest first.
- FARLONG HOLDING Corp (Mar 2026)
- Innovation Beverage Group Ltd (Mar 2026)
Watch Shuttle Pharmaceuticals Holdings, Inc.
Get an email when Shuttle Pharmaceuticals Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Shuttle Pharmaceuticals Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Shuttle Pharmaceuticals Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Shuttle Pharmaceuticals Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock is listed on the Nasdaq Capital Market under the symbol “SHPH.” The closing price of our common stock on the Nasdaq Stock Market on February 5, 2026, was $1.57 per share.From the S-1/A filed 2026-02-11
Shares offered
We are offering up to 2,229,300 shares of our common stock, at an assumed public offering price of $1.57, which is equal to the closing price per share of our common stock on The Nasdaq Capital Market, on February 5, 2026, pursuant to this prospectus.From the S-1/A filed 2026-02-11
Use of proceeds
We intend to use the net proceeds from this offering to fund Phase II clinical trials for our lead product candidate radiation sensitizer Ropidoxuridine, including $2.8 million in payments that will be owed to Theradex Systems, Inc., the CRO supporting our Phase II clinical trials, along with up to $2.0 million for certain anticipated marketing fees.From the S-1/A filed 2025-03-05
Revenue
We will retain that status until the earliest of (a) the last day of the fiscal year which we have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth in the Jobs Act) or more;From the S-1 filed 2024-09-20
Net loss or income
The Company has not generated any revenues, incurred losses since inception and has a net loss of approximately $9.1 million and no revenues for the fiscal year ended December 31, 2024 and has working capital of approximately $0.7 million as of December 31, 2024.From the S-1/A filed 2025-03-05
Withdrawal
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission consent to the withdrawal of the Company’s registration statement on Form S-1 (File No. 333-278535), together with all exhibits thereto (collectively, the “Registration Statement”).From the RW filed 2025-01-22
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-20 | Registration statement filed | S-1 |
| 2024-10-18 | Registration statement amended | S-1/A |
| 2024-10-31 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-01-15 | Registration statement filed | S-1 |
| 2025-01-22 | Request to withdraw a registration (Form S-1) | RW |
| 2025-02-13 | Registration statement filed | S-1 |
| 2025-03-05 | Registration statement amended | S-1/A |
| 2025-08-05 | Registration statement filed | S-1 |
| 2025-11-18 | Registration statement filed | S-1 |
| 2025-12-11 | Registration statement amended | S-1/A |
| 2026-02-11 | Registration statement filed | S-1 |
| 2026-02-11 | Registration statement amended | S-1/A |
Shuttle Pharmaceuticals Holdings, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Shuttle Pharmaceuticals Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.